What Does Protagonist Therapeutics Do?

Total employees144
HeadquartersNewark
Founded2006

Protagonist Therapeutics (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel peptide-based drugs to address significant unmet medical needs. Their primary focus is on inflammatory and immunomodulatory diseases, as well as rare blood disorders like polycythemia vera. Utilizing a proprietary technology platform, Protagonist engineers targeted oral and injectable peptide therapeutics designed to offer improved efficacy, safety, and patient convenience. Key pipeline candidates include rusfertide (PTG-300) for polycythemia vera and JNJ-2113 (formerly PN-235), an oral IL-23 receptor antagonist being developed in partnership with Johnson & Johnson for psoriasis and potentially other IL-23 mediated diseases.

Where Is Protagonist Therapeutics's Headquarters?

HQ Function

Serves as the primary hub for research and development, clinical operations, and corporate administration, driving the discovery and advancement of peptide-based therapeutics.

Notable Features:

The facility houses state-of-the-art laboratories for peptide synthesis, screening, and analytical chemistry, alongside office space supporting its scientific, clinical, and administrative teams. Specific architectural highlights are not widely publicized.

Work Culture:

The work culture at Protagonist Therapeutics emphasizes innovation, scientific rigor, collaboration, and a patient-centric approach. It aims to foster a dynamic and challenging environment conducive to cutting-edge biopharmaceutical research and development.

HQ Significance:

The Newark headquarters is central to Protagonist's R&D engine, facilitating the discovery, preclinical, and clinical development of its novel peptide drug candidates. Its location in the San Francisco Bay Area provides access to a rich talent pool and a vibrant biotech ecosystem.

Values Reflected in HQ: The headquarters likely reflects the company's core values of scientific excellence and innovation through its advanced R&D facilities, and collaboration through its workspace design, all geared towards improving patient outcomes.

Location:

Protagonist Therapeutics maintains a global presence primarily through its international clinical trial operations, which span North America, Europe, and the Asia-Pacific region. The company also engages in strategic global collaborations, exemplified by its partnership with Janssen (a Johnson & Johnson company) for the worldwide development and commercialization of JNJ-2113. Its direct research footprint includes its headquarters in California, USA, and an office in Brisbane, Australia.

Street Address:

770 multiflora Drive

City:

Newark

State/Province:

CA

Country:

USA

Where Else Does Protagonist Therapeutics Operate Around the World?

Brisbane, Queensland/Australia

Address: Level 7, 300 Ann Street, Brisbane, QLD 4000, Australia (Note: This is a common business address; specific suite may vary)

This location facilitates access to Australian research talent, clinical trial sites, and may leverage R&D incentives or collaborations within the Asia-Pacific biomedical ecosystem.

Buying Intent Signals for Protagonist Therapeutics

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Who's Leading Protagonist Therapeutics? Meet the Executive Team

As of April 2025, Protagonist Therapeutics' leadership includes:

Dinesh V. Patel, Ph.D. - President and Chief Executive Officer
Thadd S. Reidy, J.D., M.B.A. - Chief Financial Officer
Samuel L. Saks, M.D. - Chief Development Officer
Arturo Molina, M.D., M.S. - Chief Medical Officer
Suneel K. Gupta, Ph.D. - Chief Technical Operations Officer
Ashish S. Kulkarni, Ph.D. - Chief Scientific Officer
Donald L. Kalkofen, J.D. - Chief Legal Officer, Chief Compliance Officer & Corporate Secretary

Who's Investing in Protagonist Therapeutics?

Protagonist Therapeutics has been backed by several prominent investors over the years, including:

RA Capital Management, L.P.
BlackRock Inc.
Vanguard Group, Inc.
NEA Management Company, LLC
EcoR1 Capital, LLC
Point72 Asset Management, L.P.
Deep Track Capital, LP

What Leadership Changes Has Protagonist Therapeutics Seen Recently?

Hire2
Exits1

In the past year, Protagonist Therapeutics has strategically enhanced its leadership team with key appointments in scientific and technical operations, aligning with its pipeline advancement and growth. Notable changes include a new Chief Scientific Officer and a new Chief Technical Operations Officer.

Departures

David Y. Liu, Ph.D., Dr. David Y. Liu retired from his position as Chief Scientific Officer after significant contributions to the company.

New Appointments:

Ashish S. Kulkarni, Ph.D., Dr. Ashish S. Kulkarni appointed as the new Chief Scientific Officer to lead the company's discovery and research initiatives.
Suneel K. Gupta, Ph.D., Dr. Suneel K. Gupta joined as Chief Technical Operations Officer to strengthen manufacturing and technical development capabilities.

What Technology (Tech Stack) Is Used byProtagonist Therapeutics?

Discover the tools Protagonist Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Protagonist Therapeutics Email Formats and Examples

Protagonist Therapeutics likely uses standard corporate email address formats. While not officially published, a common pattern for companies of this nature is [first_initial][last_name]@[companydomain.com]. Other potential formats could include [first_name].[last_name]@[companydomain.com].

[first_initial][last]@protagonist-inc.com

Format

jdoe@protagonist-inc.com

Example

85%

Success rate

What's the Latest News About Protagonist Therapeutics?

GlobeNewswire • May 9, 2024

Protagonist Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Protagonist Therapeutics announced its financial results for the first quarter of 2024, highlighting progress in its clinical programs, including updates on rusfertide for polycythemia vera and JNJ-2113 (in partnership with J&J) for psoriasis. The company also reported its cash position and outlined upcoming milestones....more

Protagonist Therapeutics Press Release • March 4, 2024

Protagonist Therapeutics Announces Publication of Rusfertide Phase 2 REVIVE Study Results in The New England Journal of Medicine

Protagonist Therapeutics announced that the comprehensive results from its Phase 2 REVIVE study evaluating rusfertide in patients with polycythemia vera were published in The New England Journal of Medicine, underscoring the drug's potential efficacy and safety....more

GlobeNewswire • February 27, 2024

Protagonist Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

The company reported its financial results for the fourth quarter and full year 2023, detailing significant advancements in its pipeline, particularly for rusfertide and the JNJ-2113 program. Key achievements from the year and anticipated catalysts were also discussed....more

Highperformr's free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Protagonist Therapeutics, are just a search away.